Lineage Cell Therapeutics Inc

LCTXNYSE MKT LLC

Health CareBiotechnology

$1.33

+0.000000 (+0.00%)

As of 05/29/26 EDT · USD

Compare

52-Week Low: $0.6500Current: $1.3352-Week High: $2.09

Key Statistics

Open

$1.32

Day High

$1.36

Day Low

$1.32

Prev. Close

$1.33

Volume

625.32K

Avg. Volume

—

Market Cap

$331.57M

P/E (TTM)

-4.76

Forward P/E

—

P/B Ratio

—

52W High

$2.09

52W Low

$0.6500

50D MA

$1.46

200D MA

$1.59

Dividend Yield

—

Beta

—

Performance

+0.8%

-8.9%

-23.6%

YTD

-18.9%

+100.0%

About

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

lineagecell.com/